ABEV vs PG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ABEV's deterministic health score is weak with a Piotroski F-Score of 4/9, indicating marginal financial stability. The stock trades above the Graham Number of $2.24 at a current price of $2.78, suggesting modest overvaluation for a defensive stock, though below the growth-based intrinsic value of $5.9. Strong profitability metrics like a 17.73% profit margin and 26.01% operating margin are offset by declining revenue growth of -5.70% YoY and a concerning 104.3% dividend payout ratio. Analysts rate it a 'hold' with a $2.93 target, implying limited upside.
PG exhibits a stable financial foundation with a Piotroski F-Score of 6/9, but it is severely overvalued relative to its deterministic baselines. The current price of $145.71 represents a massive premium over the Graham Number ($58.45) and Intrinsic Value ($47.25), while a PEG ratio of 3.92 indicates the valuation is disconnected from its stagnant growth. Negative earnings growth (-5.40% YoY) combined with bearish insider activity and a 0/100 technical trend suggests significant downside risk despite the company's operational efficiency.
Compare Another Pair
Related Comparisons
ABEV vs PG: Head-to-Head Comparison
This page compares Ambev S.A. (ABEV) and The Procter & Gamble Company (PG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.